Investor Fact Sheet

Corporate Profile

HeartWare International Inc. is a global medical device company dedicated to delivering safe, high-performing and transformative therapies that enable patients with heart failure to get back to life. The company’s innovative technologies are creating advances in the miniaturization of Ventricular Assist Devices (VADs) leading to less invasive surgical procedures and increasing the patient population who may be suitable for VAD therapy.

Heart failure is a degenerative, terminal disease affecting more than 20 million patients worldwide and causing more than 7.25 million deaths each year. Approximately 1 million patients suffer from Class IV heart failure, the most severe stage of the disease. Heart transplantation is a proven treatment option for Class IV heart failure patients, but a limited number of donor hearts become available each year. Ventricular assist devices can provide circulatory support until a donor heart becomes available (called bridge-to-transplant therapy), or, provide long-term support as an alternative to transplantation (called destination therapy in many countries).

HeartWare’s breakthrough innovations begin with the company’s miniaturized ventricular assist device, called the HVAD® Pump, designed to be implanted next to the heart in the pericardial space avoiding the more invasive surgical procedures required with older LVAD technologies.

HeartWare® Ventricular Assist System Featuring the HVAD Pump Available Around the World

The HeartWare Ventricular Assist System obtained U.S. market approval in 2012 from the U.S. Food and Drug Administration (FDA) as a bridge-to-transplant therapy for patients with advanced stage heart failure. The HeartWare® System has been commercially available in other global markets including Europe and Australia, since 2009. To date, more than 9,000 patients worldwide have been treated with the HeartWare Ventricular Assist System.

HeartWare’s corporate headquarters are in Framingham, Massachusetts. The company’s operating and manufacturing activities are based in Miami Lakes, Florida, and Sydney, NSW, Australia.

Stock Quote

HeartWare

HTWR (NASDAQ)
Price
-$
Change (%)
- (%)
Volume
-

Recent Reports

Voluntary Sale Facility Extended to 1 June 2014
ASX Removal from Official List 2013
September Reminder Letter
June 17, 2013 Letter to CDI holders
Frequently Asked Questions
Delisting Letter and Timetable
Voluntary Share Sale Facility Form
Register Removal Request Form
Form W-8BEN
Recent News & Events

09/30/16 - 9:23 a.m.
FDA Classifies Two Field Actions Related to HeartWare HVAD System as Class 1 Recalls

08/23/16 - 9:09 a.m.
Medtronic Completes Acquisition of HeartWare International

07/28/16 - 8:00 a.m.
HeartWare International Reports $68.7 Million In Second Quarter 2016 Revenue

There are currently no events scheduled.

SEC Filings

<table>
<thead>
<tr>
<th>Filing Date</th>
<th>Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>02/10/17</td>
<td>SC 13G/A</td>
</tr>
<tr>
<td>01/20/17</td>
<td>SC 13G/A</td>
</tr>
<tr>
<td>09/27/16</td>
<td>SC TO-I/A</td>
</tr>
<tr>
<td>09/02/16</td>
<td>15-12B</td>
</tr>
</tbody>
</table>

Corporate Governance

Doug Godshall  
Executive Director, President and Chief Executive Officer

Larry Knopf  
Senior Vice President, General Counsel and Secretary

Jeff LaRose  
Executive Vice President, Chief Scientific Officer

Katrin Leadley, M.D.  
Chief Medical Officer

Peter McAree  
Senior Vice President, Chief Financial Officer and Treasurer

Jim Schuermann  
Senior Vice President, Sales and Marketing

Mark Strong  
Senior Vice President, Research & Development and Quality